IRWD - Ironwood Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Ironwood Pharmaceuticals, Inc.

301 Binney Street
Cambridge, MA 02142
United States

IndustryDrugs - Generic
Full Time Employees730

Key Executives

NameTitlePayExercisedYear Born
Dr. Peter M. HechtCo-Founder, CEO & Director108.06k2.76M1964
Dr. Mark G. CurrieChief Scientific Officer, Pres of R&D and Sr. VP763.04k6.08M1955
Ms. Halley E. GilbertSr. VP, Chief Legal Officer & Sec.711.04k315.6k1970
Mr. Thomas A. McCourtSr. VP of Marketing & Sales and Chief Commercial Officer731.04kN/A1957
Mr. Brian M. Cali Ph.D.Co-Founder and Sr. VP of R&D Strategy & External InnovationN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, and Macau; and a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Ironwood Pharmaceuticals, Inc.’s ISS Governance QualityScore as of March 1, 2018 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.